Three separate asset management firms launched exchange-traded funds on Tuesday, unveiling products focused on securitized ...

Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk today announced the presentation of 13 abstracts at the upcoming 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), which will take place from 7 to 10 ...

We recently published a list of 12 Most Profitable Pharmaceutical Stocks Right Now. In this article, we are going to take a ...

In a closed-door meeting at Novo's Denmark headquarters about two months ago, the India team raised concerns that the company ...

Few companies garner as much reliable attention as Novo Nordisk (NYSE: NVO) does these days. With a bull market coinciding ...

When leaders at Novo Nordisk Canada Inc. (NNCI) wanted to focus on diversity, equity, inclusion and belonging efforts for ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...

Novo Nordisk is working to accelerate the launch of its weight-loss drug Wegovy in India, concerned about lagging behind Eli ...

Novo Nordisk (NYSE: NVO ), the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. However, the Danish pharmaceutical began because of more ...